# US 2025/0367176 A1 · Methods of treating gastrointestinal stromal tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367176 A1
- Document ID: US20250367176A1
- Status: Published application
- Kind: A1
- Application number: 19/194,583
- Filed: 2025-04-30
- Published: 2025-12-04
- Earliest claimed: 2019-08-12
- Assignees: Deciphera Pharmaceuticals, LLC
- Applicants: Deciphera Pharmaceuticals, LLC
- Inventors: Rodrigo Ruiz Soto; Oliver Rosen; Jama Pitman
- Web page: https://patentgrep.com/patent/US20250367176A1

## CPC

- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/12: Antihypertensives
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.

## Claims

### Claim at position 1

1-3. (canceled)

### Claim 4

A method of treating a Grade 2, Grade 3, or Grade 4 treatment-emergent adverse event in a patient suffering from an advanced gastrointestinal stromal tumor while being administered 100 to 600 mg ripretinib daily comprising:
withholding administration of ripretinib for 7 days;
administering to the patient 100 to 600 mg ripretinib once daily if the patient achieves a less than or equal to Grade 1 of the treatment-emergent adverse event, or administering to the patient 100 mg ripretinib once daily for at least 28 days if the patient does not achieve a less than or equal to Grade 1 of the treatment-emergent adverse event;
wherein the treatment-emergent adverse event is selected from the group consisting of alopecia, fatigue, nausea, constipation, decreased appetite, diarrhea, weight decreased, lipase increased, muscle spasms, abdominal pain, vomiting, anemia, cough, dry skin, dyspnea, headache, back pain, dizziness, rash, hypokalaemia, hypophosphataemia, actinic keratosis, blood bilirubin increase, amylase increased, insomnia, seborrhoeic keratosis, urinary tract infection, dysgeusia, pain in extremity, blood creatine phosphokinase increased, upper respiratory tract infection, rash maculo-papular, hypomagnesaemia, pruritus, skin papilloma, and vision blurred.

### Claim 5 (depends on 4)

The method of claim 4, wherein the treatment-emergent adverse event is a Grade 3 treatment-emergent adverse event.

### Claim 6 (depends on 4)

The method of claim 4, wherein the treatment-emergent adverse event is a Grade 2 treatment-emergent adverse event.

### Claim 7 (depends on 4)

The method of claim 4, wherein the patient has the treatment-emergent adverse event while being administered 100 to 300 mg ripretinib daily.

### Claim 8 (depends on 4)

The method of claim 4, wherein the patient has the treatment-emergent adverse event while being administered 150 mg ripretinib once daily.

### Claim 9 (depends on 4)

The method of claim 4, wherein the patient has the treatment-emergent adverse event while being administered 150 mg ripretinib twice daily.

### Claim 10 (depends on 4)

The method of claim 4, wherein the patient is administered 150 mg ripretinib daily if the patient achieves a less than or equal to Grade 1 of the treatment-emergent adverse event.

### Claim 11 (depends on 4)

The method of claim 4, wherein the method provides more than 6 months of progression free survival in the patient, as determined by mRECIST 1.1, after at least one cycle of 42 days of the daily ripretinib administration.

### Claim 12 (depends on 4)

The method of claim 4, wherein the advanced gastrointestinal stromal tumor has a wild-type KIT mutation.

### Claim 13 (depends on 4)

The method of claim 4, wherein the advanced gastrointestinal stromal tumor has a wild-type PDGFRA mutation.
